학술논문
Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.
Document Type
Article
Author
Source
Frontiers in Pediatrics; 2024, p1-6, 6p
Subject
Language
ISSN
22962360